Cargando…
Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis
BACKGROUND: Biomarkers of inflammation predictive of cystic fibrosis (CF) disease outcomes would increase the power of clinical trials and contribute to better personalization of clinical assessments. A representative patient cohort would improve searching for believable, generalizable, reproducible...
Autores principales: | Liou, Theodore G., Adler, Frederick R., Argel, Natalia, Asfour, Fadi, Brown, Perry S., Chatfield, Barbara A., Daines, Cori L., Durham, Dixie, Francis, Jessica A., Glover, Barbara, Heynekamp, Theresa, Hoidal, John R., Jensen, Judy L., Keogh, Ruth, Kopecky, Carol M., Lechtzin, Noah, Li, Yanping, Lysinger, Jerimiah, Molina, Osmara, Nakamura, Craig, Packer, Kristyn A., Poch, Katie R., Quittner, Alexandra L., Radford, Peggy, Redway, Abby J., Sagel, Scott D., Sprandel, Shawna, Taylor-Cousar, Jennifer L., Vroom, Jane B., Yoshikawa, Ryan, Clancy, John P., Elborn, J. Stuart, Olivier, Kenneth N., Cox, David R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485181/ https://www.ncbi.nlm.nih.gov/pubmed/31027503 http://dx.doi.org/10.1186/s12874-019-0705-0 |
Ejemplares similares
-
The Future of Highly Effective Modulator Therapy in Cystic Fibrosis
por: Daines, Cori L., et al.
Publicado: (2021) -
Acute pulmonary embolism in a child with ANCA-negative idiopathic pulmonary capillaritis
por: Asseri, Ali A., et al.
Publicado: (2019) -
Developing Future Clinical Pharmacy Leaders in the Interprofessional Care of Children with Special Health Care Needs and Medical Complexity (CSHCN-CMC) in a Pediatric Pulmonary Center
por: Hobart, Catherine B., et al.
Publicado: (2019) -
Treatment adherence and health outcomes in patients with bronchiectasis
por: McCullough, Amanda R, et al.
Publicado: (2014) -
Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial
por: Griese, Matthias, et al.
Publicado: (2021)